This work was supported by NIH R01 HL-095470, NIH R01 HL-083388, NIH U01 HL-42799, NIH N01 HB-42972, and NIH RO1 HL-067229.
Leukoreduction and ultraviolet treatment reduce both the magnitude and the duration of the HLA antibody response
Article first published online: 30 JUN 2013
© 2013 American Association of Blood Banks
Volume 54, Issue 3, pages 672–680, March 2014
How to Cite
Jackman, R. P., Deng, X., Bolgiano, D., Utter, G. H., Schechterly, C., Lebedeva, M., Operskalski, E., Luban, N. L., Alter, H., Busch, M. P., Slichter, S. J. and Norris, P. J. (2014), Leukoreduction and ultraviolet treatment reduce both the magnitude and the duration of the HLA antibody response. Transfusion, 54: 672–680. doi: 10.1111/trf.12317
- Issue published online: 11 MAR 2014
- Article first published online: 30 JUN 2013
- Manuscript Accepted: 14 MAY 2013
- Manuscript Revised: 12 APR 2013
- Manuscript Received: 21 MAR 2013
- NIH. Grant Numbers: R01 HL-095470, R01 HL-083388, U01 HL-42799, N01 HB-42972, RO1 HL-067229
Both leukoreduction and ultraviolet (UV) light treatment of blood products have been shown to reduce the incidence of HLA antibody development in recipients, but the impact of these treatments on the magnitude and persistence of the antibody response is less clear.
Study Design and Methods
Longitudinal samples from 319 subjects taken from four different study cohorts were evaluated for HLA antibodies to determine the effects of leukoreduction and UV treatment on HLA antibody generation and persistence.
Subjects receiving leukoreduced or UV-treated blood products were less likely to generate Class I HLA antibodies, and those receiving leukoreduced blood were also less likely to generate Class II HLA antibodies. Among those receiving nonleukoreduced blood, 55% developed Class I HLA antibodies and 51% developed Class II HLA antibodies compared with 28% (Class I) and 15% (Class II) for those receiving leukoreduced blood and 36% (Class I) and 54% (Class II) for those receiving UV-treated blood. Among alloimmunized subjects, leukoreduction resulted in a significant twofold reduction in the magnitude of Class I HLA antibodies, and UV treatment resulted in a significant threefold reduction in the magnitude of Class II HLA antibodies. Both treatments resulted in shorter persistence of Class I HLA antibodies.
These data demonstrate that leukoreduction and UV treatment of blood products results not only in a reduction in the incidence of HLA antibody production, but also in lower and more transient HLA antibody levels among sensitized transfusion recipients.